证券代码：300721 证券简称:怡达股份 公告编号：2025-036 第五届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏怡达化学股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日上 午 9:00 在公司会议室召开第五届董事会第七次会议，本次会议由刘准董事长主 持，本次会议应出席会议的董事为 7 人，实际出席会议董事 7 人，公司部分高级 管理人员列席了会议。本次会议的召开符合《公司法》及《公司章程》中有关董 事会召开的有关规定。 二、董事会会议审议情况 1、 《关于控股子公司收购股权的议案》 江苏怡达化学股份有限公司 经与会董事认真审议并通过投票表决的方式通过了如下决议： 基于公司战略发展和经营发展需要，为优化公司产业布局，提高公司竞争力， 经交易双方友好协商，公司控股子公司泰兴怡达拟以现金方式收购江苏万淇生物 科技股份有限公司持有的万淇生物科技（泰州）有限公司 85%股权，股权转让价 格为 2,456.50 万元。本次交易完成后，泰兴怡达将持有万淇生物科技（泰州） 有限公司 85% ...

格隆汇11月24日丨怡达股份(300721.SZ)在投资者互动平台表示，公司暂无扩产环氧丙烷产能的计划。 ...

Core Viewpoint - Yida Co., Ltd. announced the completion of the share reduction plan implemented by its director and CFO, Ms. Sun Yinfeng [2] Summary by Relevant Sections - Company Announcement - Yida Co., Ltd. has received a notice from its director and CFO regarding the completion of the share reduction plan [2]

Core Insights - Yida Co., Ltd. (300721.SZ) released its Q3 2025 financial report on October 25, 2025, indicating a total institutional holding of 1.1509 million shares, representing 0.70% of the total share capital [1] - The institutional holding ratio decreased by 0.10 percentage points compared to the previous quarter [1] Institutional Investors - As of October 24, 2025, there is one institutional investor holding shares in Yida Co., Ltd., which is Wuxi Shenyin Investment Enterprise (Limited Partnership) [1] - The total institutional holding ratio stands at 0.70% [1] Public Funds - In this reporting period, seven public funds were disclosed, which were not reported in the previous quarter [1] - Notable public funds include Zhongzheng 2000, Western Gain Quantitative Preferred One-Year Holding Mixed A, Southern Zhongzheng 2000 ETF, and others [1]

Core Insights - The company reported a revenue of 1.11 billion yuan for the first three quarters, representing a year-on-year decline of 16.56% [1] - The net loss for the period was 89.83 million yuan, with a non-recurring net loss of 90.12 million yuan [1] - The basic earnings per share were reported at -0.5449 yuan [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Yida Co., which reported a revenue of approximately 1.11 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 16.56% [1] - The net profit attributable to shareholders of the listed company showed a loss of approximately 89.83 million yuan [1] - The basic earnings per share reported a loss of 0.5449 yuan [1] Group 2 - The article also discusses the broader context of the Chinese innovative pharmaceutical market, noting that overseas licensing has generated sales of 80 billion US dollars this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, who comments on the hot secondary market for biomedicine while indicating that fundraising in the primary market is facing challenges [1]

Core Viewpoint - The company reported a significant decline in revenue and incurred a net loss for the first three quarters of 2025 [1] Financial Performance - The company's operating revenue for the first three quarters was 1.11 billion yuan, representing a year-on-year decrease of 16.56% [1] - The net loss attributable to shareholders of the listed company was 89.83 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 90.12 million yuan [1] - The basic loss per share was 0.5449 yuan [1]

Core Viewpoint - The company reported a significant decline in revenue and incurred substantial net losses in the first three quarters of 2025 [1] Financial Performance - The company's operating revenue for the first three quarters was 1.11 billion yuan, representing a year-on-year decrease of 16.56% [1] - The net loss attributable to shareholders of the listed company was 89.8277 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 90.1157 million yuan [1] - The basic loss per share was 0.5449 yuan [1]

Financial Performance - The company's revenue for Q3 2025 was ¥419,995,765.76, representing a decrease of 8.47% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥26,843,912.96, a significant decline of 1,582.30% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥27,093,740.17, down 1,539.54% from the previous year[5] - Total operating revenue decreased to ¥1,110,353,176.52 from ¥1,330,711,783.62, a decline of approximately 16.6% year-over-year[17] - Net profit for the period was a loss of ¥107,713,897.54, compared to a profit of ¥6,068,843.65 in the previous period, indicating a significant downturn[18] - The total comprehensive income attributable to shareholders was a loss of ¥-89,827,730.38, compared to a gain of ¥14,426,402.31 in the prior year[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,559,910,606.28, a decrease of 2.83% from the end of the previous year[5] - Total assets decreased from 2,634,363,081.76 CNY to 2,559,910,606.28 CNY, a decline of about 2.8%[15] - The total liabilities increased to ¥1,431,188,523.62 from ¥1,398,546,275.46, marking an increase of approximately 2.4%[16] - The total equity attributable to shareholders decreased to ¥1,128,722,082.66 from ¥1,217,953,134.51, a decline of about 7.3%[16] Cash Flow - The company reported a cash flow deficit from operating activities of ¥114,836,126.42, a decline of 196.08% compared to the same period last year[9] - The company's net cash flow from operating activities was negative at ¥-114,836,126.42, contrasting with a positive cash flow of ¥119,521,220.77 in the prior year[20] - Cash inflow from financing activities reached 955,579,300.00 thousand, with cash outflow totaling 848,923,267.14 thousand, leading to a net cash flow of 106,656,032.86 thousand[21] - The net increase in cash and cash equivalents was -81,563,318.80 thousand, compared to an increase of 12,716,743.61 thousand in the previous period[21] - The ending balance of cash and cash equivalents stood at 106,412,545.84 thousand, down from 165,322,512.89 thousand in the prior period[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,112[11] - The top shareholder, Liu Zhun, holds 20.80% of shares, totaling 34,295,684 shares[11] Operational Changes - The company plans to accelerate the implementation of the "220,000 tons/year epoxy propylene (ethylene) derivative technical transformation project" to enhance product quality and reduce costs[10] - The company aims to strengthen cost control and improve profitability in response to the complex competitive environment[10] - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board of directors[12] - The company has completed the registration of changes related to the abolishment of the supervisory board and the revision of internal control systems[12] Expenses - The company experienced a significant increase in accounts receivable financing, which rose by 139.53% to ¥129,914,215.72 due to an increase in notes receivable[9] - The company's management expenses decreased by 42.57% to ¥39,453,243.60, primarily due to reduced downtime losses[9] - Research and development expenses were reduced to ¥12,828,606.01 from ¥15,571,710.39, a decrease of approximately 17.7% year-over-year[17] - The company reported a significant increase in tax expenses, with income tax expenses of ¥-32,916,469.69 compared to ¥-760,672.79 in the previous period[18] Inventory and Receivables - Accounts receivable increased from 128,372,264.58 CNY to 156,746,931.47 CNY, representing a growth of about 22.1%[14] - Inventory decreased from 310,231,075.60 CNY to 259,291,832.40 CNY, a reduction of approximately 16.4%[14] Other Information - The company's cash and cash equivalents decreased from 215,774,621.98 CNY to 132,000,845.84 CNY, a decline of approximately 38.9%[14] - The company has not audited its third-quarter financial report[22]

Core Viewpoint - Nova Star Cloud announced the initiation of its third share repurchase program, reflecting the company's commitment to enhancing shareholder value through strategic buybacks [1] Summary by Categories Share Repurchase Details - The company executed its first repurchase under the third phase on October 13, 2025, acquiring 28,100 shares, which represents 0.03% of the total share capital [1] - The highest transaction price was 170.99 yuan per share, while the lowest was 169.63 yuan per share, with a total transaction amount of 4.7838 million yuan (excluding transaction fees) [1] - This repurchase aligns with the company's repurchase plan and complies with relevant laws and regulations [1]